China, Sept. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Bispecific Antibody Combined with a Novel BCL-2 Inhibitor for the Treatment of Pediatric B-cell Acute Lymphoblastic Leukemia'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600132240
Registration Time: 2026/09/10
Type: Observational study
Primary Sponsor: Beijing Childrens Hospital,Capital Medical University
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=340431
Published by HT Digital Content Services with permission from Health Daily Digest....